Belite Bio, Inc
Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and … Read more
Belite Bio, Inc (D01) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2024: -0.032x
Based on the latest financial reports, Belite Bio, Inc (D01) has a cash flow conversion efficiency ratio of -0.032x as of December 2024.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-4.60 Million) by net assets (€145.82 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Belite Bio, Inc - Cash Flow Conversion Efficiency Trend (2021–2024)
This chart illustrates how Belite Bio, Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Belite Bio, Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Belite Bio, Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Country Garden Holdings Company Ltd
PINK:CTRYF
|
0.251x |
|
EZconn Corp
TW:6442
|
0.165x |
|
Frasers Logistics & Commercial Trust
PINK:FRLOF
|
0.029x |
|
Life Insurance Corporation Of India
NSE:LICI
|
0.007x |
|
DWS Group GmbH & Co. KGaA
XETRA:DWS
|
0.046x |
|
Yihai Kerry Arawana Holdings Co Ltd
SHE:300999
|
0.140x |
|
Cargotec Corporation
PINK:CYJBF
|
0.053x |
|
Silvercorp Metals Inc
NYSE MKT:SVM
|
0.151x |
Annual Cash Flow Conversion Efficiency for Belite Bio, Inc (2021–2024)
The table below shows the annual cash flow conversion efficiency of Belite Bio, Inc from 2021 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €145.82 Million | €-29.23 Million | -0.200x | +39.24% |
| 2023-12-31 | €90.43 Million | €-29.84 Million | -0.330x | -19.51% |
| 2022-12-31 | €41.50 Million | €-11.46 Million | -0.276x | -155.75% |
| 2021-12-31 | €-15.09 Million | €-7.47 Million | 0.495x | -- |